Can you tell me more about bglc press release tomorrow?

**Bottom line (what to expect)**
BioNexus Gene Lab Corp. (BGLC 📈) is slated to issue a combined **earnings / corporate-update press release before the U.S. market opens tomorrow, Wed July 2, 2025 (~08:30 a.m. ET)**. According to the event calendars that flag micro-cap news flows, the release will:

1. Report FY-2025 Q1 results (quarter ended Mar 31).
2. Formally introduce newly-hired CFO **Ms. Chong Set Fui** and outline her immediate priorities.
3. Provide color on the two “story-drivers” that powered yesterday’s +260 % breakout:
• progress in its RNA-based liquid-biopsy pipeline and
• early traction at subsidiary Chemrex after expanding into higher-margin colour-paste production.

Because the company only regained Nasdaq compliance in late April and remains a ~$20 m micro-cap, any fresh numbers or strategic pivots can move the tape **violently**.

---

### Key items likely to appear in tomorrow’s release

| Focus area | Why it matters for the tape | Benchmarks to watch |
|------------|----------------------------|---------------------|
| Revenue growth (biotech service + industrial chemicals) | Even low-single-digit topline beats tend to squeeze shorts in thin float names | Street whisper **$2.8 m – $3.0 m** for the quarter |
| Cash & runway | Cash burn ran ~$0.7 m/qtr in FY-24. ≤ $2 m cash would raise dilution fears. | Cash ≥ $3 m and burn ≤ 0.6 m would be read as “safer” |
| Nasdaq bid-price compliance strategy | Reverse-split in April fixed the $1 rule; mgmt must show plan to stay compliant | Any mention of further equity raises or split-adjusted share count |
| CFO commentary | First public remarks from Ms. Chong since her 6-23 appointment; credibility check | New cost-controls / audit process / U.S. banking relationships |
| Pipeline timeline | Liquid-biopsy CLIA validation or Malaysia MOH approvals could ignite “blue-sky” talk | Concrete milestone dates rather than vague ambitions |

---

### Trading implications 🚨

1. **Pre-market knee-jerk.** Micro-cap biotech PRs typically hit GlobeNewswire or BusinessWire at 07:00-08:30 ET; algos react within seconds.
2. **Liquidity is razor-thin.** Yesterday’s 1,400 × volume spike leaves many shorts trapped; a positive headline could fuel another squeeze into the open.
3. **Binary profile.** If the release disappoints on cash or guidance, BGLC can retrace 30-50 % just as quickly—size positions accordingly.

---

### Prep checklist for tomorrow’s session 🗓️🔍

• Set news-alerts for “BGLC” on your terminal at 07:00 ET.
• Have pre-defined levels (e.g., $9.00 support, $14.50 breakout high) and tight risk limits.
• Watch sympathy names in micro-cap diagnostics (MBIO, GOVX) for momentum spill-over.

Good luck navigating the catalyst—stay nimble and protect capital! Feel free to ping me at the open if you need a real-time read on the numbers. 🚀🤞